Skip to main content
Premium Trial:

Request an Annual Quote

MPI's Oncology Venture, Lantern Pharma Receive $800K Award to Advance Prostate Cancer Drug Using a Biomarker

NEW YORK(GenomeWeb) – Medical Prognosis Institute today announced its drug development arm, Oncology Venture, and Lantern Pharma have received an $800,000 grant to support their efforts to advance an antitumor agent for treating metastatic castration-resistant prostate cancer with the use of a biomarker developed by MPI.

The grant was awarded under the Life Sciences International Collaborative Industry Program, which is administered by the Massachusetts Life Sciences Center. 

Irofulven is a transcription-coupled repair-specific antitumor agent that has shown promise in earlier clinical trials but has not reached suitable efficacy endpoints. Under the partnership, OV and Lantern will use an irofulven-specific biomarker developed by MPI to identify patients with metastatic castration-resistant prostate cancer who are likely to respond to the drug. Those patients would be enrolled in a targeted Phase II trial for irofulven, whose rights are held by Lantern. 

MPI developed the biomarker with its Drug Response Predictor platform, which can be used to identify patients who are likely to respond to drug treatments. Its transcriptomics-based approach combines gene expression profiling with systems biology analytics, according to MPI's website. 

OV acquires and invests in cancer drugs that have previously failed clinical efficacy trials but can be repurposed for the right indication and right patients through the Drug Response Predictor platform, MPI said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more